💥 Merck and Moderna’s personalized mRNA cancer vaccine, intismeran autogene (mRNA-4157/V940), is designed from each patient’s tumor mutations to train T cells to recognize and attack residual cancer. Combined with Keytruda, which removes a PD-1 immune checkpoint “brake,” it aims to strengthen and sustain that tumor-specific immune response.
AlgoTrader 